Cognitive changes in mice following moderate MPTP exposure

Brain Research Bulletin

Volumn 45, Issue 6, 1998, Pages 577-582

  Tanila, Heikki ^a   Björklund, Markus ^a   Riekkinen Jr , Paavo ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Alpha 2 adrenoceptor; Dopamine; Mouse; Parkinsonism; Spatial memory

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; COGNITION; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; INTRAPERITONEAL DRUG ADMINISTRATION; MAZE TEST; MOUSE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; SPATIAL MEMORY; TASK PERFORMANCE; VISUAL DISCRIMINATION;

EID: 0032051751     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(97)00452-8     Document Type: Article

References (41)

1. Arai N., Misugi K., Goshima Y., Misu Y. Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism. Brain Res. 515:1990;57-63.
2. 2-noradrenergic mechanisms to prefrontal cortical cognitive function. Arch. Gen. Psychiatry. 53:1996;448-455.
3. Arnsten A. F. T., Goldman-Rakic P. S. Catecholamines and cognitive decline in aged nonhuman primates. Ann. NY Acad. Sci. 444:1985;218-234.
4. Bubser M., Schmidt W. J. 6-Hydroxydopamine lesion of the rat prefrontal cortex increases locomotor activity, impairs acquisition of delayed alternation tasks, but does not affect uninterrupted tasks in the radial maze. Behav. Brain Res. 37:1990;157-168.
5. Burns R., Chiueh C., Markey S. P., Ebert M. H., Jacobowitz D. M., Kopin I. J. A primate model of parkinsonism Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine . Proc. Natl. Acad. Sci. 80:1983;4546-4550.
6. Carlson J. N., Herrick K. F., Baird J. L., Glick S. D. Selective enhancement of dopamine utilization in the rat prefrontal cortex by food deprivation. Brain Res. 400:1987;200-203.
7. Date I., Felten D. L., Felten S. Y. Long-term effect of MPTP in the mouse brain in relation to aging Neurochemical and immunochemical analysis . Brain Res. 519:1990;266-276.
8. Dluzen D. E., Kreutzberg J. D. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) disrupts social memory/recognition processes in the male mouse. Brain Res. 609:1993;98-102.
9. Ferre S., Prat G., Guix T., Goma M., Jane F., Casas M. T-maze performance in rats following chronic neuroleptic treatment. Pharmacol. Biochem. Behav. 35:1990;481-484.
10. Fredriksson A., Archer T. MPTP-induced behavioural and biochemical deficits A parametric analysis . J. Neural. Transm. 7:1994;123-132.
11. Heikkila R. E., Hess A., Duvoisin R. C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Science. 224:1984;1451-1453.
12. Hietanen M., Teräväinen H. Cognitive performance in early Parkinson's disease. Acta Neurol. Scand. 73:1986;151-159.
13. Jäkälä, P.; Riekkinen, M.; Sirviö, J.; Koivisto, E.; Kejonen, K.; Vanhanen, M.; Riekkinen, P., Jr. Guanfacine, but not clonidine, improves planning of working memory performance in humans, Neuropsychopharmacology (in press).
14. Jäkälä P., Sirviö J., Jolkkonen J., Riekkinen P Jr, Acsady L., Riekkinen P Sr. The effects of p-chlorophenylalanine-induced serotonin synthesis inhibition and muscarinic blockade on the performance of rats in a 5-choice serial reaction time task. Behav. Brain Res. 51:1992;29-40.
15. Koulu M., Pesonen U., Koskinen S., Scheinin H., Virtanen R., Scheinin M. Reduced turnover of dopamine and 5-hydroxytryptamine in discrete dopaminergic, noradrenergic and serotonergic rat brain areas after acutely administered medetomidine, a selective alpha 2-adrenoceptor agonist. Pharmacol. Toxicol. 72:1993;182-187.
16. Lategan A. J., Marien M. R., Colpaert F. C. Effects of locus coeruleus lesions on the release of endogenous dopamine in the rat nucleus accumbens and caudate nucleus as determined by intracerebral microdialysis. Brain Res. 523:1990;134-138.
17. Levin B. E., Llabre M. M., Weiner W. J. Cognitive impairments associated with early Parkinson's disease. Neurology. 39:1989;557-561.
18. MacDonald E., Scheinin M., Scheinin H., Virtanen R. Comparison of the behavioral and neurochemical effects of the two optical enantiomers of medetomidine, a selective alpha-2-adrenoceptor agonist. J. Pharmacol. Exp. Ther. 259:1991;848-854.
19. Mogensen J., Iversen I. H., Divac I. Neostriatal lesions impaired rats' delayed alternation performance in a T-maze but not in a two-key operant chamber. Acta Neurobiol. Exp. 47:1987;45-54.
20. Murphy B. L., Arnsten A. F. T., Jentsch J. D., Roth R. H. Dopamine and spatial working memory in rats and monkeys pharmacological reversal of stress-induced impairment . J. Neurosci. 16:1996;7768-7775.
21. Ogawa N., Mizukawa K., Hirose Y., Kajita S., Ohara S., Watanabe Y. MPTP-induced parkinsonian model in mice biochemistry, pharmacology and behavior . Eur. Neurol. 26:(Suppl. 1):1987;16-23.
22. Owen A. M., Beksinska M., James M., Leigh P. N., Summers B. A., Marsden C. D., Quinn N. P., Sahakian B. J., Robbins T. W. Visuospatial memory deficits at different stages of Parkinson's disease. Neuropsychologia. 31:1993;627-644.
23. Owen A. M., Roberts A. C., Hodges J. R., Summers B. A., Polkey C. E., Robbins T. W. Contrasting mechanisms of impaired attentional set-shifting in patients with frontal lobe damage or Parkinson's disease. Brain. 116:1993;1159-1175.
24. Owen A. M., Sahakian B. J., Hodges J. R., Summers B. A., Polkey C. E., Robbins T. W. Dopamine-dependent fronto-striatal planning deficits in early Parkinson's disease. Neuropsychology. 9:1995;126-140.
25. Packard M. G., McGaugh J. L. Inactivation of hippocampus or caudate nucleus with lidocaine differentially affects expression of place and response learning. Neurobiol. Learn. Mem. 65:1996;65-72.
26. Pycock C. J., Kerwin R. W., Carter C. J. Effects of lesion of cortical dopamine terminals on subcortical dopamine in rats. Nature. 286:1980;74-77.
27. Reading P. J., Dunnett S. B. 6-hydroxydopamine lesions of nigrostriatal neurons as an animal model of Parkinson's disease. Woodruff M. L., Nonnenman A. J. Toxin-induced models of neurological disorders. 1994;89-119 New York, Plenum Press.
28. 2-reseptors in mediating their inhibitory effects on [3H] dopamine release from rat nucleus accumbens slices. Neurochem. Res. 18:1993;285-289.
29. 2-adrenoceptor agonist.
30. Schneider J. S. Chronic exposure to low doses of MPTP II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys . Brain Res. 534:1990;25-36.
31. Schneider J. S., Kovelowski C. J. Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Brain Res. 519:1990;122-128.
32. Schneider J. S., Roeltgen D. P. Delayed matching-to-sample, object retrieval, and discrimination reversal deficits in chronic low dose MPTP-treated monkeys. Brain Res. 615:1993;351-354.
33. Simon H., Taghzouti K., Le Moal M. Deficits in spatial-memory tasks following lesions of septal dopaminergic terminals in the rat. Behav. Brain Res. 19:1986;7-16.
34. Stam C. J., de Bruin J. P., van Haelst A. M., van der Gugten J., Kalsbeek A. Influence of the mesocortical dopaminergic system on activity, food hoarding, social-agonistic behavior, and spatial delayed alternation in male rats. Behav. Neurosci. 103:1989;24-35.
35. Stern Y., Langston J. W. Intellectual changes in patients with MPTP-induced parkinsonism. Neurology. 35:1985;1506-1509.
36. Sundström E., Henriksson B. G., Mohammed A. H., Souverbie F. MPTP-treated mice A useful model for Parkinson's disease? Woodruff M. L., Nonnenman A. J. Toxin-induced models of neurological disorders. 1994;121-137 New York, Plenum Press.
37. Taylor A. E., Saint-Cyr J. A., Lang A. E. Frontal lobe dysfunction in Parkinson's disease. Brain. 109:1986;845-883.
38. Thierry A. M., Godbout R., Mantz J., Glowinski J. Influence of the ascending monoaminergic systems on the activity of the rat prefrontal cortex. Prog. Brain Res. 85:1990;357-364.
39. Tombaugh T. N., Szostak C., Mills P. Failure of pimozine to disrupt the acquisition of light-dark and spatial discrimination problems. Psychopharmacology. 79:1983;161-168.
40. Weihmuller F. B., Hadjiconstantinou M., Bruno J. P. Dopamine receptors and sensorimotor behavior in MPTP-treated mice. Behav. Brain Res. 38:1990;263-273.
41. Wikmark R. G. E., Divac I., Weiss R. Retention of spatial delayed alternation in rats with lesions in the frontal lobes. Brain Behav. Evol. 8:1973;329-339.